# UK Percutaneous Coronary Intervention Market > UK Percutaneous Coronary Intervention Market Research Report By Product Type (Coronary Stents, Ballon Catheters, Coronary Guidewires, Guiding Catheters, Guiding Sheaths, Diagnostic Catheters, Crossing Catheters, Inflation Device, Guidance System, Peripheral Thrombectomy System, Embolic Protection System, Accessories), By Vascular Access (Radial, Femoral) and By End User (Hospitals Clinics, Ambulatory Surgical Centers, Others) -Forecast to 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 10.0% - **2024:** $ 643.28 Million - **2025:** $ 707.61 Million - **2035:** $ 1,836 Million - **Key Players:** Abbott Laboratories (US), Boston Scientific Corporation (US), Medtronic plc (IE), Johnson & Johnson (US), B. Braun Melsungen AG (DE), Terumo Corporation (JP), Cardinal Health, Inc. (US), Siemens Healthineers AG (DE) **Report ID:** MRFR/HC/43692-HCR · **Pages:** 200 · **Author:** Satyendra Maurya & Rahul Gotadki · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/uk-percutaneous-coronary-intervention-market-45372 --- ## Market Summary ## **UK Percutaneous Coronary Intervention Market Overview** As per MRFR analysis, the UK Percutaneous Coronary Intervention Market Size was estimated at 398.76 (USD Million) in 2023.The UK Percutaneous Coronary Intervention Market is expected to grow from 438.75 (USD Million) in 2024 to 1,096.88 (USD Million) by 2035. The UK Percutaneous Coronary Intervention Market CAGR (growth rate) is expected to be around 8.687% during the forecast period (2025-2035). **Key UK Percutaneous Coronary Intervention Market Trends Highlighted** An aging population and rising cardiovascular disease incidence are driving major market trends in the UK percutaneous coronary intervention (PCI) industry. Since heart-related problems continue to be a major health concern in the UK, the National Health Service (NHS) highlights the need for efficient treatment alternatives. Minimally invasive procedures are becoming more and more popular because they satisfy patients' desires for quicker recovery times and shorter hospital stays. PCI is becoming more widely used as a result of improvements in procedural success rates brought about by technological developments in imaging and catheter design. There are clear development prospects in the UK industry as healthcare providers look to reduce expenses and enhance patient outcomes. Given the NHS's ongoing efforts to deliver effective care, hospitals and medical device makers can work together to create creative solutions. Furthermore, early detection and treatment of coronary artery disorders are being encouraged by the public's increased health consciousness and adoption of preventative measures, which will ultimately lead to an expansion of the PCI market. Adopting dual antiplatelet therapy and other adjuvant treatments in addition to PCI has been increasingly popular in recent years as a way to enhance patient recovery and lower the risk of complications. As medical professionals use genetic and biomarker testing to customize treatment regimens for patients, the emphasis on personalized medicine is also crucial. In keeping with developments in precision medicine, this movement guarantees safer and more effective interventions. With an emphasis on improved patient experience and cardiovascular health outcomes, these trends and drivers all point to a strong market environment for PCI in the UK. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **UK Percutaneous Coronary Intervention Market Drivers** **Increasing Incidence of Cardiovascular Diseases** Cardiovascular diseases (CVDs) represent a significant health challenge in the UK, with statistics indicating that CVDs are responsible for nearly one in four deaths. The British Heart Foundation reports that approximately 7.4 million people in the UK are living with heart and circulatory diseases. As the population ages, the prevalence of these diseases is expected to rise, subsequently increasing the demand for surgical intervention options, including percutaneous coronary interventions (PCIs). The UK Percutaneous Coronary Intervention Market is poised for growth as healthcare providers and patients explore more effective treatment options in light of advancing medical technologies. Initiatives from organizations like the NHS and Heart Foundation aim to improve the treatment landscape, actively contributing to an environment that supports the expansion of PCI capabilities. Furthermore, with ongoing developments in minimally invasive techniques that enhance patient recovery, the market for PCI is likely to expand significantly as patients seek safer and more effective coronary treatments. **Technological Advancements in PCI Procedures** Recent technological advancements in the UK Percutaneous Coronary Intervention Market have introduced innovations such as bioresorbable stents and improved imaging techniques, which play a crucial role in enhancing the efficacy and safety of procedures. The National Institute for Health and Care Excellence (NICE) has supported the adoption of these technologies, providing guideline updates that mission to improve patient outcomes. Emerging techniques like optical coherence tomography (OCT) have significantly improved visualization during procedures, allowing for optimized stent placement and reduced complications. As these technologies become more widely adopted by clinical practices across the UK, the overall market for PCI is projected to grow steadily in the coming years. **Increased Healthcare Expenditure on Cardiovascular Treatments** The UK government has steadily increased healthcare expenditure, with a notable focus on improving cardiovascular health. The NHS Long-Term Plan outlines a commitment to dedicate resources toward innovative treatment options, including percutaneous coronary interventions. In 2020, healthcare spending accounted for almost 10% of the UK's GDP, indicating a strong commitment to disease management and prevention. This focus translates into enhanced funding for PCI procedures, resulting in a more robust UK Percutaneous Coronary Intervention Market. The growing emphasis on preventive care and treatment accessibility aims to reduce the burden of cardiovascular diseases, further stimulating market growth. **Aging Population Driving Market Demand** The aging population in the UK is a significant driver for the UK Percutaneous Coronary Intervention Market. According to the Office for National Statistics, the percentage of people aged 65 and over in the UK is projected to increase from 18% in 2019 to 24% by 2043. This demographic shift leads to higher prevalence rates of chronic conditions such as coronary artery disease, requiring interventions like PCI. As older adults are more susceptible to heart diseases, the demand for effective coronary treatment options is expected to soar. This increased need will likely drive growth in the PCI sector as healthcare providers seek to meet the requirements of this expanding population segment. **UK Percutaneous Coronary Intervention Market Segment Insights** **Percutaneous Coronary Intervention Market Product Type Insights** The UK Percutaneous Coronary Intervention Market exemplifies a vital role in modern cardiovascular care, encompassing various product types that cater to different procedural needs within cardiac interventions. Among these, Coronary Stents have carved out a significant presence, primarily due to their effectiveness in maintaining arterial patency and preventing restenosis, which is crucial for improving patient outcomes post-procedure. Ballon Catheters follow closely, as they serve an essential role in achieving arterial dilation, complementing stenting procedures and enhancing the efficacy of angioplasty techniques that are widely performed across the UK. Additionally, Coronary Guidewires are imperative in navigating the complex anatomy of coronary vessels during interventions, contributing to successful procedural outcomes by ensuring accurate positioning of devices. Likewise, Guiding Catheters and Guiding Sheaths play an instrumental role in providing access and stabilizing the delivery of interventional devices into coronary arteries, a necessity for achieving precision during interventions. Diagnostic Catheters, which are used for imaging and hemodynamic assessments, underscore the importance of accurate diagnosis leading to effective treatment strategies. The inclusion of Crossing Catheters reflects the increasing focus on advancing techniques to cross chronic total occlusions, addressing a challenging aspect of coronary artery disease treatment. Other supportive devices like Inflation Devices are critical for effective deployment of balloons and stents, while Guidance Systems that offer real-time imaging and navigation aid are becoming more prevalent, enhancing procedural efficiency and safety. The Peripheral Thrombectomy System, along with Embolic Protection Systems, further demonstrates the focus on protecting patients from complications during interventions and minimizing risks associated with thrombosis. It’s worth noting the substantial importance of Accessories in facilitating various procedural components, evidencing their contribution towards enhancing the overall quality of interventions. In summary, the diverse range of product types in the UK Percutaneous Coronary Intervention Market not only illustrates significant advancements within the industry but also indicates ongoing innovation driven by the aim to improve patient care and procedural outcomes in an evolving landscape of cardiovascular health management across the region. With the healthcare ecosystem increasingly integrating advanced technologies and techniques, the prospects for growth in these product categories remain promising, responding effectively to the rising prevalence of coronary artery diseases and the need for efficient treatment options. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **Percutaneous Coronary Intervention Market Vascular Access Insights** The Vascular Access segment within the UK Percutaneous Coronary Intervention Market plays a crucial role in defining the success of interventional cardiac procedures. This segment provides the necessary means for accessing the vascular system, which is essential for delivering therapeutic interventions efficiently. Notably, the Radial access technique has gained traction in the UK due to its favorable outcomes, including reduced complication rates and quicker patient recovery, thus facilitating smoother procedural workflows. The Femoral access method, while traditional, still holds significant importance, particularly in cases that require extensive intervention, highlighting its relevance in complex procedures. As healthcare systems in the UK continue to evolve, adopting innovative techniques, both pathways ensure a comprehensive approach to vascular access, catering to diverse patient needs. Overall, advancements in technology and clinician training have bolstered the efficacy and safety of vascular access techniques, making them a pivotal focus within the UK Percutaneous Coronary Intervention Market. **Percutaneous Coronary Intervention Market End User Insights** The UK Percutaneous Coronary Intervention Market, focusing on the End User segment, showcases a diverse landscape characterized by various healthcare settings. Hospitals and clinics stand out as critical contributors due to their capacity to incorporate advanced surgical technologies and skilled personnel, thus meeting a significant portion of the growing demand for interventional procedures. Ambulatory surgical centers are also gaining traction, providing patients with a more streamlined and cost-effective option for surgical treatments, which aligns with the NHS's initiatives to enhance patient care efficiency. Additionally, the 'Others' category encompasses a mix of facilities that play niche roles in delivering specialized care, further enriching the market landscape. This segmentation reflects broader trends within the UK healthcare ecosystem, particularly the shift towards more accessible and efficient healthcare options driven by demographic changes and an increasing prevalence of cardiovascular diseases. Overall, each segment carries importance and contributes to the continuous growth and evolution of the UK Percutaneous Coronary Intervention Market, as healthcare providers adapt to meet the needs of a dynamic patient population. **UK Percutaneous Coronary Intervention Market Key Players and Competitive Insights** The UK Percutaneous Coronary Intervention Market is a dynamic and evolving sector within the medical device industry, characterized by a competitive landscape that encompasses a range of companies specializing in cardiovascular devices and services. The market has witnessed significant advancements due to technological innovations, increased prevalence of cardiovascular diseases, and a growing aging population seeking effective treatment options. Key players within this market strive to enhance patient outcomes through the development of innovative products such as stents, balloon catheters, and other interventional devices that facilitate minimally invasive procedures. Competitive intelligence in this sector highlights the importance of product differentiation, regulatory compliance, and customer relationships as companies continuously seek to establish their market presence while addressing the unique needs of healthcare providers and patients in the UK. B. Braun Melsungen AG holds a prominent position in the UK Percutaneous Coronary Intervention Market, leveraging its robust product portfolio and commitment to innovation. The company is recognized for its comprehensive range of medical devices specifically designed to improve the efficacy of interventional procedures in cardiology. B. Braun has made significant investments in research and development to ensure that its offerings meet the stringent requirements of healthcare regulations while delivering high-quality solutions to cardiovascular specialists. The company's strengths lie in its established brand reputation, extensive distribution channels, and a strong focus on customer support, which collectively enhance its competitive edge in the UK market. B. Braun's commitment to education and training for healthcare professionals further establishes its role as a trusted partner in the percutaneous coronary intervention sector. Terumo Corporation plays a crucial role in the UK Percutaneous Coronary Intervention Market, highlighted by its advanced technologies and product innovations tailored for cardiovascular treatment. The company provides a wide array of medical devices, including high-performance guidewires, balloon catheters, and stents, which facilitate minimally invasive procedures central to percutaneous interventions. Terumo's market presence in the UK is reinforced by its strategic collaborations and partnerships that drive research initiatives and expand its product offerings. The company’s strength lies in its focus on quality assurance, ongoing product improvements, and an emphasis on meeting the specific needs of healthcare providers and patients. Through various mergers and acquisitions, Terumo has enhanced its capabilities in the cardiovascular device sector, enabling it to deliver cutting-edge solutions that align with the evolving demands of the UK healthcare landscape. The combination of innovative technology, strong market presence, and dedication to patient-centered solutions positions Terumo as a significant player in this competitive market. **Key Companies in the UK Percutaneous Coronary Intervention Market Include** - B. Braun Melsungen AG - Terumo Corporation - LivaNova - Johnson and Johnson - Hansen Medical - Boston Scientific - Siemens Healthineers - Stryker Corporation - Philips - eV3 - Accelerated Care Plus - Abbott Laboratories - Medtronic - Cardinal Health - Cook Medical **UK Percutaneous Coronary Intervention****Market****Developments** Recent developments in the UK Percutaneous Coronary Intervention Market have highlighted significant advancements and trends among leading players, particularly B. Braun Melsungen AG, Terumo Corporation, Abbott Laboratories, and Medtronic. With an ongoing emphasis on enhancing patient outcomes, there is a notable uptick in the adoption of innovative PCI technologies, influenced by the increasing prevalence of coronary artery diseases in the UK. In terms of market valuation, growth has been propelled by rising investments in research and development, with major companies actively seeking to expand their product portfolios. Notable mergers and acquisitions in the sector include Abbott Laboratories acquiring a strategic interest in a cardiac device startup in September 2021, enhancing their capabilities in catheter technologies. Similarly, Boston Scientific's acquisition of a smaller tech firm specializing in advanced imaging for PCI in May 2022 has strengthened their competitive positioning. In the last couple of years, initiatives from the UK’s National Health Service to improve the efficiency of PCI procedures are shaping the landscape by promoting best practices and technology integration. These developments signify a dynamic market climate responding to both technological advances and healthcare demands within the UK. **UK Percutaneous Coronary Intervention Market Segmentation Insights** **UK Percutaneous Coronary Intervention Market****Product Type****Outlook** **UK Percutaneous Coronary Intervention Market****Vascular Access****Outlook** **UK Percutaneous Coronary Intervention Market****End User****Outlook** -   -   -   -   -   - Beta Beta feature -   -   -   -   -   - Beta Beta feature ## Market Drivers ### Rising Healthcare Expenditure The increase in healthcare expenditure in the UK is a significant driver for the percutaneous coronary-intervention market. With the government and private sectors investing more in healthcare infrastructure and technology, there is a greater availability of resources for advanced cardiac care. Recent reports indicate that healthcare spending in the UK has risen by approximately 5% annually, with a substantial portion allocated to cardiovascular treatments. This financial commitment is likely to enhance the accessibility and quality of percutaneous interventions, thereby stimulating market growth. As funding continues to improve, the percutaneous coronary-intervention market is expected to benefit from enhanced service delivery and patient outcomes. ### Growing Focus on Preventive Healthcare The increasing emphasis on preventive healthcare measures in the UK is influencing the percutaneous coronary-intervention market. As healthcare policies shift towards prevention and early intervention, there is a heightened awareness of cardiovascular health among the population. Initiatives aimed at educating the public about heart health and the importance of regular screenings are likely to lead to earlier diagnoses and timely interventions. This proactive approach may result in a higher demand for percutaneous procedures as patients seek to manage their cardiovascular risks effectively. Consequently, the percutaneous coronary-intervention market is poised for growth as preventive strategies become more ingrained in healthcare practices. ### Advancements in Medical Imaging Technologies Innovations in medical imaging technologies are playing a pivotal role in enhancing the precision and outcomes of percutaneous coronary interventions. Techniques such as intravascular ultrasound (IVUS) and optical coherence tomography (OCT) are becoming increasingly integrated into clinical practice in the UK. These advancements allow for better visualization of coronary anatomy, leading to improved decision-making during procedures. The integration of these technologies is expected to drive growth in the percutaneous coronary-intervention market, as they contribute to higher success rates and reduced complications. As healthcare providers continue to invest in advanced imaging solutions, the market is likely to witness a significant uptick in procedural volumes. ### Aging Population and Associated Health Risks The demographic shift towards an aging population in the UK is a critical driver for the percutaneous coronary-intervention market. As individuals age, the prevalence of cardiovascular diseases tends to increase, necessitating more frequent interventions. Current statistics indicate that approximately 40% of individuals over 65 years old experience some form of cardiovascular condition. This demographic trend suggests a sustained demand for percutaneous interventions, as healthcare systems adapt to the needs of older patients. Consequently, the percutaneous coronary-intervention market is likely to expand in response to the growing number of elderly patients requiring treatment, thereby shaping the future landscape of cardiovascular care. ### Increasing Demand for Minimally Invasive Procedures The percutaneous coronary-intervention market is experiencing a notable shift towards minimally invasive procedures, driven by patient preference for reduced recovery times and lower complication rates. As healthcare providers in the UK increasingly adopt these techniques, the market is projected to grow significantly. According to recent data, minimally invasive cardiac procedures have shown a 30% increase in adoption over the past five years. This trend is likely to continue as advancements in technology enhance the safety and efficacy of these interventions. Furthermore, the growing awareness among patients regarding the benefits of such procedures is expected to further fuel demand, thereby positively impacting the percutaneous coronary-intervention market. ## Future Outlook The [Percutaneous Coronary Intervention Market](https://www.marketresearchfuture.com/reports/percutaneous-coronary-intervention-market-3166) is projected to grow at a 10.0% CAGR from 2025 to 2035, driven by technological advancements, increasing prevalence of cardiovascular diseases, and rising healthcare expenditure. **New opportunities:** - Development of advanced catheter technologies for improved patient outcomes. - Expansion of telehealth services for remote monitoring and follow-up care. - Partnerships with insurance providers to enhance reimbursement models for procedures. By 2035, the market is expected to achieve substantial growth, reflecting evolving healthcare dynamics. ## Segment Insights ### By Product Type: Coronary Stents (Largest) vs. Balloon Catheters (Fastest-Growing) In the UK percutaneous coronary-intervention market, the product type segment is primarily dominated by Coronary Stents, which holds the largest market share among the different devices used for cardiac interventions. Following closely are Balloon Catheters, regarded for their significant contributions to the segment. Other critical players include Coronary Guidewires and Guiding Catheters, which also maintain a notable presence in the market landscape. The growth trends for this segment are primarily driven by advancements in technology and the increasing prevalence of cardiovascular diseases. Balloon Catheters have emerged as the fastest-growing product type, attributed to innovations enhancing their efficiency and performance. Moreover, the rising adoption of minimally invasive procedures is bolstering the demand for various devices within this segment, including Accessories and Diagnostic Catheters, further indicating positive market dynamics leading toward sustained growth. Coronary Stents (Dominant) vs. Balloon Catheters (Emerging) Coronary Stents maintain their status as the dominant product in the UK percutaneous coronary-intervention market due to their proven efficacy in treating coronary artery diseases and their high rate of utilization in interventional procedures. These devices are critical in providing structural support within coronary arteries post-angioplasty. In contrast, Balloon Catheters, as an emerging segment, are rapidly gaining traction due to their innovative designs and capabilities in achieving effective vessel dilation. Their growing prevalence in minimally invasive surgeries highlights their importance, as they are often used in tandem with stent placement procedures. The ongoing advancements in both product types continue to shape the competitive landscape, catering to various patient needs and enhancing procedural outcomes. ### By Vascular Access: Radial (Largest) vs. Femoral (Fastest-Growing) In the UK percutaneous coronary-intervention market, the radial access approach holds the largest market share, widely preferred by cardiologists for its benefits including reduced complications and faster recovery. In contrast, femoral access, historically the primary approach, is witnessing a significant increase in adoption, particularly among specific patient demographics that require more complex interventions. The growth of the femoral segment can be attributed to advancements in medical technology and increasing awareness of its efficacy in challenging cases. Furthermore, robust clinical outcomes coupled with favorable patient experiences are driving its rise. As procedural innovations continue to emerge, both segments are expected to see sustained engagement, but the femoral approach may accelerate as practitioners adapt to evolving best practices. Radial (Dominant) vs. Femoral (Emerging) The radial access method is established as the dominant choice in the UK percutaneous coronary-intervention market. Its advantages include lower rates of bleeding and major vascular complications, leading to quicker patient recovery and discharge times. Clinically backed studies highlight its safety and efficacy, solidifying its role in routine interventions. On the other hand, femoral access, once the standard, is evolving into an emerging option, particularly in complex cases. Despite some residual bias towards radial access, innovations and enhanced training for femoral procedures are catalyzing its resurgence. Overall, while radial access maintains a stronghold, femoral access is carving a niche that could expand significantly in the future. ### By End User: Hospitals & Clinics (Largest) vs. Ambulatory Surgical Centers (Fastest-Growing) In the UK percutaneous coronary-intervention market, Hospitals & Clinics dominate the end-user segment, accounting for a significant share of the market. This segment benefits from the high volume of cardiovascular procedures performed in these facilities, reflecting their established infrastructure and advanced technologies. Ambulatory Surgical Centers, although smaller in share, are rapidly gaining traction due to their efficiency and lower costs for patients, thereby increasing their appeal. Growth trends in this market segment are driven by various factors, including the rising prevalence of cardiovascular diseases and the growing preference for minimally invasive procedures. Innovations in medical technologies and an increasing number of healthcare policies promoting outpatient services are further propelling the expansion of Ambulatory Surgical Centers. This shift is indicative of a broader trend toward value-based care, which emphasizes patient outcomes and cost efficiency in the delivery of healthcare services. Hospitals & Clinics (Dominant) vs. Ambulatory Surgical Centers (Emerging) Hospitals & Clinics in the UK percutaneous coronary-intervention market represent the dominant end-user segment due to their comprehensive facilities and expertise in managing complex cardiovascular conditions. These institutions are equipped with state-of-the-art technologies and multidisciplinary teams, ensuring high-quality patient care. Ambulatory Surgical Centers, on the other hand, are emerging as a viable alternative, particularly for less complicated procedures, offering patients convenience and reduced wait times. As the healthcare landscape evolves, these centers are becoming increasingly important, catering to a growing consumer base that seeks effective treatment options without the need for overnight stays. ## Competitive Benchmarking The percutaneous coronary-intervention market is characterized by a dynamic competitive landscape, driven by technological advancements, increasing prevalence of cardiovascular diseases, and a growing aging population. Key players such as Abbott Laboratories (US), Boston Scientific Corporation (US), and Medtronic plc (IE) are at the forefront, each adopting distinct strategies to enhance their market presence. Abbott Laboratories (US) focuses on innovation, particularly in drug-eluting stents, while Boston Scientific Corporation (US) emphasizes strategic partnerships to expand its product portfolio. Medtronic plc (IE) is actively pursuing regional expansion, particularly in emerging markets, which collectively shapes a competitive environment that is both collaborative and competitive.In terms of business tactics, companies are increasingly localizing manufacturing to reduce costs and enhance supply chain efficiency. The market structure appears moderately fragmented, with several key players exerting influence over various segments. This fragmentation allows for niche players to thrive, while larger corporations leverage their resources to optimize operations and capture market share. In October Boston Scientific Corporation (US) announced a strategic partnership with a leading UK-based healthcare provider to enhance access to its innovative coronary intervention technologies. This collaboration is expected to facilitate the integration of advanced medical devices into routine clinical practice, thereby improving patient outcomes and solidifying Boston Scientific's position in the UK market. The strategic importance of this partnership lies in its potential to streamline distribution channels and enhance brand visibility. In September Medtronic plc (IE) launched a new generation of bioresorbable stents, which are designed to improve patient recovery times and reduce long-term complications. This product introduction not only reflects Medtronic's commitment to innovation but also positions the company to capture a growing segment of the market that prioritizes minimally invasive solutions. The launch is likely to enhance Medtronic's competitive edge by addressing evolving patient needs and preferences. In August Abbott Laboratories (US) expanded its manufacturing capabilities in the UK, investing approximately £50 million to enhance production efficiency for its coronary intervention devices. This investment underscores Abbott's commitment to meeting increasing demand while ensuring high-quality standards. The strategic importance of this expansion is multifaceted, as it not only boosts local employment but also strengthens Abbott's supply chain resilience in a competitive market. As of November current trends in the percutaneous coronary-intervention market include a pronounced shift towards digitalization, sustainability, and the integration of artificial intelligence (AI) in clinical practices. Strategic alliances are increasingly shaping the landscape, enabling companies to pool resources and expertise. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on innovation, technological advancements, and supply chain reliability, as companies strive to meet the complex demands of healthcare providers and patients alike. ## Recent News & Developments Recent developments in the UK Percutaneous Coronary Intervention Market have highlighted significant advancements and trends among leading players, particularly B. Braun Melsungen AG, Terumo Corporation, Abbott Laboratories, and Medtronic. With an ongoing emphasis on enhancing patient outcomes, there is a notable uptick in the adoption of innovative PCI technologies, influenced by the increasing prevalence of coronary artery diseases in the UK. In terms of market valuation, growth has been propelled by rising investments in research and development, with major companies actively seeking to expand their product portfolios. Notable mergers and acquisitions in the sector include Abbott Laboratories acquiring a strategic interest in a cardiac device startup in September 2021, enhancing their capabilities in catheter technologies. Similarly, Boston Scientific's acquisition of a smaller tech firm specializing in advanced imaging for PCI in May 2022 has strengthened their competitive positioning. In the last couple of years, initiatives from the UK’s National Health Service to improve the efficiency of PCI procedures are shaping the landscape by promoting best practices and technology integration. These developments signify a dynamic market climate responding to both technological advances and healthcare demands within the UK. ## Report Scope | MARKET SIZE 2024 | 643.28(USD Million) | | --- | --- | | MARKET SIZE 2025 | 707.61(USD Million) | | MARKET SIZE 2035 | 1836.0(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 10.0% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Abbott Laboratories (US), Boston Scientific Corporation (US), Medtronic plc (IE), Johnson & Johnson (US), B. Braun Melsungen AG (DE), Terumo Corporation (JP), Cardinal Health, Inc. (US), Siemens Healthineers AG (DE) | | Segments Covered | Product Type, Vascular Access, End User | | Key Market Opportunities | Integration of advanced imaging technologies enhances procedural accuracy in the percutaneous coronary-intervention market. | | Key Market Dynamics | Technological advancements and regulatory changes drive growth in the percutaneous coronary-intervention market in the UK. | | Countries Covered | UK | ## Frequently Asked Questions **Q: What is the current valuation of the UK percutaneous coronary-intervention market?** A: The market valuation was $643.28 Million in 2024. **Q: What is the projected market size for the UK percutaneous coronary-intervention market by 2035?** A: The market is projected to reach $1836.0 Million by 2035. **Q: What is the expected CAGR for the UK percutaneous coronary-intervention market during the forecast period 2025 - 2035?** A: The expected CAGR is 10.0% during the forecast period. **Q: Which product segment holds the highest valuation in the UK percutaneous coronary-intervention market?** A: Coronary Stents held a valuation of $150.0 Million in 2024 and is expected to grow significantly. **Q: What are the key players in the UK percutaneous coronary-intervention market?** A: Key players include Abbott Laboratories, Boston Scientific Corporation, and Medtronic plc, among others. **Q: How do the vascular access segments compare in terms of market valuation?** A: The Femoral segment had a valuation of $385.97 Million in 2024, while the Radial segment was valued at $257.31 Million. **Q: What is the market valuation for hospitals and clinics as end users in the UK percutaneous coronary-intervention market?** A: Hospitals & Clinics had a valuation of $386.28 Million in 2024. **Q: What is the expected growth trajectory for the coronary guidewires segment?** A: The coronary guidewires segment was valued at $80.0 Million in 2024 and is likely to see substantial growth. **Q: What is the valuation of the inflation device segment in the UK percutaneous coronary-intervention market?** A: The inflation device segment was valued at $30.0 Million in 2024. **Q: What is the projected growth for ambulatory surgical centers as end users by 2035?** A: Ambulatory Surgical Centers are projected to grow from $157.0 Million in 2024 to a higher valuation by 2035. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/uk-percutaneous-coronary-intervention-market-45372*